Short Analytical ReviewMechanism of Action for Leflunomide in Rheumatoid Arthritis
References (77)
- et al.
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
Lancet
(1999) - et al.
Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats
Int. J. Immunopharmacol.
(1989) - et al.
Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by anti-basement membrane antibody in rats
Clin. Immunol. Immunopathology
(1991) - et al.
Leflunomide prevents the development of experimentally induced myasthenia gravis
Int. J. Immunopharmacol.
(1995) - et al.
Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
J. Biol. Chem.
(1995) - et al.
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
Curr. Opin. Immunol.
(1996) - et al.
Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria
Biochem. Pharmacol.
(1998) - et al.
Purine nucleotide metabolism in phytohemagglutinin-induced human T lymphocytes
Arch. Biochem. Biophys.
(1987) - et al.
Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors
Semin. Immunol.
(1997) - et al.
Recruitment of p300/CBP in p53-dependent signal pathways
Cell
(1997)
p53, the cellular gatekeeper for growth and division
Cell
(1997)
The retinoblastoma protein and cell cycle control
Cell
(1995)
Mice lacking p21 undergo normal development, but are defective in G1 checkpoint control
Cell
(1995)
Activation-induced apoptosis in lymphocytes
Curr. Opin. Immunol.
(1994)
Leflunomide inhibits pyrimidine de novo synthesis in mitogen stimulated T-lymphocytes from healthy humans
J. Biol. Chem.
(1998)
Dihydroorotate dehydrogenase is a high affinity binding protein for A77-1726 and mediator of a range of biological effects of the immunomodulatory compound
J. Biol. Chem.
(1995)
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
Biochem. Pharmacol.
(1995)
Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase
Protein Exp. Purif.
(1998)
In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis
Transplant. Proc.
(1997)
The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition
Immunol. Today
(1995)
Lymphocyte-specific genomic instability
Semin. Immunol.
(1997)
Side effects of brequinar and brequinar analogues, in combination with cyclosporine in the rat
Toxicology
(1998)
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide
J. Biol. Chem.
(1995)
Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
Arch. Int. Med.
(1999)
Mechanism of the anti-proliferative action of leflunomide
J. Heart Lung Trans.
(1995)
Disease modifying activity of HWA 486 on the development of SLE in the MRL/lpr mouse
Agents Actions
(1986)
The use of the murine chronic graft-vs-host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery
Agent Actions
(1987)
Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide
Immunopharmacology
(1991)
A novel immunomodulating agent—leflunomide inhibits experimental autoimmune diabetes in mice
Transplant Proc.
(1996)
Immunopharmacologic properties of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjunvant arthritis in the rat
Int. J. Immunopharmacol.
(1988)
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
Transplant. Proc.
(1996)
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis
Arthritis Rheum.
(1995)
Leflunomide plus methotrexate in refractory rheumatoid arthritis: A pilot study
Arthritis Rheum.
(1999)
The immunosuppressant leflunomide inhibits the progression through the cell cycle by a novel mechanism
J. Pharm. Exp. Therapeutics
(1995)
Mechanism of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation
Transplant. Proc.
(1996)
Regulation of B cell function by the immunosuppressive agent leflunomide
Transplantation
(1996)
Leflunomide (HWA 486) and its analog suppress T and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey recipients
Transplant. Proc.
(1995)
A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
Genes Dev.
(1996)
Cited by (0)
Copyright © 1999 Academic Press. All rights reserved.